Statins reduce adverse cardiovascular events in both primary and secondary prevention settings. Despite their use, however, a residual burden of cardiovascular events continues to remain; in part this residual risk is related to low high-density lipoprotein (HDL) cholesterol levels. Therefore, HDL-based interventions that either raise HDL cholesterol levels or improve HDL function have become the next target for atherosclerosis management.
No takes yet. Share an insight, caveat, or question.
Prediman K. Shah (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: